TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37461956
Drug: Continuous ozanimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ozanimod treatment
Study: 37461956
Drug: Continuous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous placebo treatment
Study: 37462430
Drug: Vasopressin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (0.03 U/kg IV bolus followed by 0.3 mU/kg/min infusion)
Study: 37462799
Drug: Home-based computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based computerized EF intervention (5 days/week, 30 min/day, total dose 30 hours)
Study: 37463240
Drug: Ferumoxytol-enhanced CMRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol-enhanced CMRA (3 mg/kg IV)
Study: 37463344
Drug: Home-based light-intensity
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based light-intensity training with daily whey protein supplementation (LITW)
Study: 37463344
Drug: Daily whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily whey protein supplementation alone (WHEY)
Study: 37463650
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Study: 37463650
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Study: 37464107
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic Therapy
Study: 37464228
Drug: Serious game
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serious game based on Gabor patches (study group)
Study: 37464283
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block with steroid and local anesthetic drugs
Study: 37464355
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) implantation into nitrate-induced maximally dilated vessels
Study: 37464978
Drug: Warfarin 5
Normalized name: warfarin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 5 mg (CYP2C9)
Study: 37464978
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (CYP2C19)
Study: 37464978
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg (CYP3A4)
Study: 37464978
Drug: Repaglinide 0.5
Normalized name: repaglinide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 0.5 mg (CYP2C8)
Study: 37465323
Drug: Oral roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral roflumilast 500 μg once daily
Study: 37465817
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 1 mg once daily
Study: 37465817
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 2.5 mg once daily
Study: 37465817
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 5 mg once daily
Study: 37465959
Drug: Dual-task Augmented
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task Augmented Reality Treatment (DART)
Study: 37466000
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Study: 37466110
Drug: Preoperative ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ondansetron (4 mg in 100 ml of 0.9% saline 1 hour before induction of anaesthesia)
Study: 37466110
Drug: Intraoperative ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative ondansetron (4 mg in 100 ml of 0.9% saline 30 min before end of surgery)
Study: 37466566
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy
Study: 37467227
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (potassium rich diets, potassium supplements, and mineralocorticoid receptor antagonists (MRA) for six months)
Study: 37467497
Drug: GBS6 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS6 vaccine (various formulations)
Study: 37467497
Drug: GBS6 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS6 vaccine (most immunogenic formulation)
Study: 37467498
Drug: Zilebesiran (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg)
Study: 37467498
Drug: Zilebesiran (≥200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran (≥200 mg)
Study: 37467498
Drug: Zilebesiran (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran (800 mg) under high-salt diet conditions
Study: 37467498
Drug: Zilebesiran (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran (800 mg) coadministered with irbesartan
Study: 37467930
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg q3w; 16 cycles)
Study: 37468569
Drug: Palbociclib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (first-line treatment)
Study: 37468569
Drug: Palbociclib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (≥ second-line treatment)
Study: 37468978
Drug: Physical Exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Exercise (PE) combined with Cognitive Behaviour Therapy (CBT) for 15 weeks of PE and 10 weeks of CBT
Study: 39495467
Drug: Mitiperstat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiperstat 2.5 mg
Study: 39495467
Drug: Mitiperstat 5
Normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiperstat 5 mg
Study: 37470137
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus Vorinostat (DL1: 100 mg, DL2: 200 mg)
Study: 37470445
Drug: Intravenous remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous remdesivir (200 mg followed by 100 mg daily for 5 days)
Study: 37470678
Drug: Tailored music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored music listening; details on dosage and duration not available
Study: 37470772
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model based on age, waist circumference, systolic blood pressure, glycated hemoglobin, antihypertensive medication use, and early onset preeclampsia (yes/no)
Study: 37470840
Drug: Accelerated bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated bilateral theta-burst stimulation (TBS) consisting of 5 sequential bilateral intermittent TBS (600 pulses) and continuous TBS (600 pulses) daily for 5 days at 120% resting motor threshold.
Study: 37471117
Drug: Polybactum (PLGG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polybactum (PLGG) administered for 3 cycles followed by a 1-month follow-up period without treatment.
Study: 37471574
Drug: Axillary lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary lymph node dissection followed by adjuvant treatment (standard arm)
Study: 37471590
Drug: sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarilumab 200 mg every 2 weeks for 16 weeks, followed by 12 weeks of sarilumab or placebo
Study: 37473746
Drug: Sucroferric Oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric Oxyhydroxide (SFOH) 1,500 mg iron/day
Study: 37473746
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer Carbonate 2.4 g/day
Study: 37473964
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg mRNA-1273 vaccine via npMNA patch (ID-patch group)
Study: 37473964
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg mRNA-1273 vaccine via intramuscular injection (IM-control group)
Study: 37474181
Drug: Alanyl-glutamine (AQ)
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine (AQ) supplementation at doses of 4, 24, and 44 g administered daily for 10 days.
Study: 37474181
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (placebo control).
Study: 37474632
Drug: ABVD (front-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD (front-line treatment)
Study: 37474689
Drug: Drug sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug sensitivity tests on circulating tumor cell-derived organoids (cancer avatars)
Study: 37474720
Drug: Pamiparib 40
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 40 mg orally twice daily plus tislelizumab 200 mg intravenously every 3 weeks
Study: 37474729
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker use
Study: 37474761
Drug: Alcohol (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.08 g% breath alcohol concentration)
Study: 37474823
Drug: Pudexacianinium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium 0.3 mg
Study: 37474823
Drug: Pudexacianinium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium 1.0 mg
Study: 37474823
Drug: Pudexacianinium 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium 3.0 mg
Study: 37475004
Drug: palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib plus endocrine therapy (ET)
Study: 37475009
Drug: Empagliflozin treatment
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin treatment
Study: 37475009
Drug: Standard post-MI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-MI treatment (placebo)
Study: 37475036
Drug: Written physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written physical activity prescription with pedometer and logbook
Study: 37475036
Drug: Verbal advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal advice to do at least 15 minutes of rapid walking or equivalent daily
Study: 37475689
Drug: High-protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (HP) diet (40% protein) with ≥4 weekly servings of lean beef
Study: 37476150
Drug: Wear a
Normalized name: titanium dioxide 12.6 mL in 100 mL / zinc oxide 2.0 mL in 100 mL TOPICAL CREAM [REPAIRWEAR ANTI -AGING MAKEUP SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wear a patch monitor and a smartwatch linked to a smartphone running the Pulsewatch application
Study: 37476150
Drug: Only the
Normalized name: Product containing only theophylline (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only the cardiac patch monitor
Study: 37476572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of good CF and adequate LI drop
Study: 37477105
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² combined with cisplatin 75 mg/m² (HIPEC at 43°C for 90 minutes)
Study: 37477105
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m²
Study: 37477105
Drug: Docetaxel ≤65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel ≤65 mg/m²
Study: 37477788
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (5 mg) added to IIN/IHN block
Study: 37477875
Drug: ChAd155-RSV low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ChAd155-RSV low dose (1.5 × 10^10 viral particles)
Study: 37477875
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator vaccines/placebo
Study: 37477875
Drug: ChAd155-RSV (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd155-RSV (both doses)
Study: 37478213
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 5 L/minute
Study: 37478213
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow of 10 L/minute
Study: 37478283
Drug: Combined local
Normalized name: Local hemostatic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined local therapy and CAR-GPC3 T-cell therapy
Study: 37478401
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy using a self-inactivating lentiviral vector expressing human WAS complementary DNA after busulfan and fludarabine conditioning
Study: 37478529
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care followed by delayed treatment with TranS-C
Study: 37478883
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy with immunotherapy (I-SABR)
Study: 38044204
Drug: givosiran 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: givosiran 2.5 mg/kg
Study: 37479372
Drug: Venglustat (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat (15 mg/day)
Study: 37479373
Drug: AXER-204 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXER-204 (200 mg)
Study: 37479519
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy of 5 days
Study: 37479519
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy of at least 7 days
Study: 37479526
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests
Study: 37479627
Drug: Patient comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient comfort management solutions identified through qualitative interviews
Study: 37479627
Drug: Therapeutic radiographers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic radiographers' comfort management solutions identified through qualitative interviews
Study: 37479795
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-1 levels
Study: 37480004
Drug: Topical CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical CoQ10 (40% CoQ10) mucoadhesive tablets, 3 times daily for one month
Study: 37480004
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (triamcinolone acetonide 0.1% 5-g adhesive paste), 4 times daily for one month
Study: 37480087
Drug: Rapid weaning
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid weaning of opioids (morphine or methadone)
Study: 37480087
Drug: Slow weaning
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow weaning of opioids (morphine or methadone)
Study: 37480432
Drug: Dupilumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab with concomitant low-potency topical corticosteroids (TCS) every 4 weeks for 16 weeks
Study: 37480432
Drug: Dupilumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab with concomitant low-potency topical corticosteroids (TCS)
Study: 37480432
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with concomitant low-potency topical corticosteroids (TCS)
Study: 37480520
Drug: LL-37 cream
Normalized name: hydromorphone
DrugBank: LL-37 (DB16532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LL-37 cream applied twice a week for 4 weeks
Study: 37480520
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice a week for 4 weeks
Study: 37480520
Drug: LL-37 cream
Normalized name: hydromorphone
DrugBank: LL-37 (DB16532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LL-37 cream
Study: 37480994
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy plus chemotherapy (HFRT), 60 Gy over 25 fractions, administered five times each week.
Study: 37480994
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy plus chemotherapy (CFRT), 69.96 Gy over 33 fractions, administered five times each week.
Study: 37480994
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups experienced acute grade 1 or 2 toxicities including skin toxicity, oral mucositis, difficulty swallowing, xerostomia; no acute grade 3 or 4 toxicities reported.
Study: 37480994
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy plus chemotherapy (HFRT).
Study: 37480994
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy plus chemotherapy (CFRT).
Study: 37481515
Drug: HAI oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HAI oxaliplatin in combination with modified systemic FOLFIRI plus targeted therapy
Study: 37481515
Drug: Systemic FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic FOLFIRI plus targeted therapy
Study: 37481816
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) - defined as a combination of a minimum of 3 medications in 4 drug classes (antiplatelet drugs, statins, β blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).
Study: 37481816
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) in PCI group
Study: 37481816
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) in CABG group
Study: 37482172
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 20 mg/kg/d, twice daily for 4 weeks
Study: 37482926
Drug: Single FMT
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single FMT treatment
Study: 38871148
Drug: Repeated FMT
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated FMT treatments
Study: 37483544
Drug: CM310 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM310 (300 mg) every 2 weeks
Study: 37483623
Drug: Modified immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified immune cell (MIC) infusions
Study: 37483623
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (control)
Study: 37484496
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg SIM0417 plus 100 mg ritonavir
Study: 37484496
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SIM0417 plus 100 mg ritonavir
Study: 37485397
Drug: Multiple drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drugs given per routine care
Study: 37485564
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day on days 1-14 of every 21-day cycle in combination with R-ESHAP at standard doses
Study: 37485589
Drug: Inhaled oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled oxytocin 240 IU (400 μg) IH
Study: 37485589
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin 10 IU (17 μg) IM
Study: 37485589
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin 5 IU (8.5 μg) IV
Study: 37485589
Drug: Inhaled oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled oxytocin (Group 1)
Study: 37485589
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin (Group 1)
Study: 37485589
Drug: Inhaled oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled oxytocin (Group 2)
Study: 37485887
Drug: Hypoglycaemia (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (2.8 ± 0.1 mmoL/L [49.9 ± 2.3 mg/dL])
Study: 37486343
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy after PARPi progression
Study: 37486343
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy after progression on PARPi
Study: 37486372
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy combined with partial splenic embolization (EP group)
Study: 37486372
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy alone (E group)